Market Reports center has added new Research Report – Global Autoimmune and Inflammatory Immunomodulators Market 2016-2020
Report recognizes the following companies as the key players in the global autoimmune and inflammatory immunomodulators market: AbbVie, Johnson & Johnson, Amgen, F. Hoffmann-La Roche, and Pfizer.
Other prominent vendors in the market are: AstraZeneca, Avaxia Biologics, Biogen Idec, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Enlivex Therapeutics, Gilead Sciences, Immune Pharmaceuticals, Merck, Mitsubishi Tanabe Pharma, Neovacs, Prometheus Laboratories, Sandoz, Sanofi, Swedish Orphan Biovitrum, Takeda Pharmaceuticals, and UCB.
Request for sample @ https://marketreportscenter.com/request-sample/455986
Commenting on the report, an analyst from our team said: “One of latest trends in the market is emergence of oral agents likely to improve patient outcomes. The advent of oral agents in the treatment of rheumatoid arthritis and IBD are expected to have a positive impact on the market growth. For instance, JAK inhibitors such as Xeljanz are expected to become standard therapies in the future, owing to the reduced complications during the administration of drug. Many individuals are reluctant to use injectable medications. Therefore, vendors are increasingly focusing on developing oral agents for the treatment of rheumatoid arthritis. For example, in February 2016, Pfizer received the US FDA approval of Xeljanz XR (tofacitinib citrate), an oral JAK inhibitor, for the treatment of rheumatoid arthritis. As there is an increased need for oral therapies, the new product will substantially fuel the market growth in the future.”
Check Discount on report @ https://marketreportscenter.com/request-discount/455986
According to the report, one of the primary drivers in the market is strong adoption of TNF-alpha inhibitors and B-cell inhibitors. The physicians prefer to adopt TNF-alpha inhibitors and B-cell inhibitors, owing to their established clinical profiles. For instance, AbbVie’s Humira, targeted at autoimmune and other inflammatory indications, reported a worldwide revenue of approximately $14 billion in 2015, indicating an approximate growth of 12% year-on-year (YoY). The strong growth of Humira is attributed to the increasing prescription volume across various therapy areas, including rheumatoid arthritis and IBD. Also, TNF-alpha inhibitors such as Cimzia are posting substantial revenues owing to the increased adoption rates. Cimzia, a treatment for rheumatoid arthritis and Crohn’s disease and other autoimmune diseases, reported revenue of $1.2 billion, indicating a YoY growth of 36% (base currencies).
Further, the report states that one major challenge in the market is discontinuation of drugs under development leading to substantial loss of revenue. Discontinuation of the drugs under development or from the market after its launch due to non-satisfactory safety or efficacy result is a major challenge for the market. Discontinuation in the late stages of development or from the market will lead to a heavy loss in revenues because of the high R&D and marketing costs invested by the company. Discontinuation of rheumatoid arthritis and IBD drugs is high as the drug target is not properly understood before the drug trial commences. Also, the drugs are sometimes discontinued at the later stages of the trial as unacceptable adverse effects appear on the body.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. For further information on this report, please visit- https://marketreportscenter.com/reports/455986/global-autoimmune-and-inflammatory-immunomodulators-market-2016-2020
You can also reach me if you have any questions or need any assistance
Market Reports Center